Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Core Insights - Palisade Bio, Inc. presented positive preclinical data for PALI-2108, a colon-specific PDE4 inhibitor prodrug aimed at treating ulcerative colitis, demonstrating its efficacy in modulating inflammatory pathways and promoting a favorable immune response [1][3][6] - The company is advancing a Phase 1a/b study of PALI-2108, which has shown a favorable safety profile in single-ascending-dose cohorts [1][3] Preclinical Study Findings - PALI-2108 was tested in a mouse model of colitis, showing significant improvements in clinical parameters such as Disease Activity Index (DAI), body weight, and colon length in a dose-dependent manner [6] - The treatment resulted in a marked reduction of PDE4B expression in colon tissues, increased cAMP levels, and notable suppression of TNF-α compared to standard treatments like cyclosporine A and apremilast [6] - The study utilized 4% dextran sulfate sodium (DSS) to induce colitis in mice, with various dosages of PALI-2108 administered [3][6] Pharmacokinetics and Safety - Pharmacokinetic modeling indicated that PALI-2108 has favorable absorption and bioavailability, supporting its potential for clinical use [4] - The preclinical data highlighted minimal CNS toxicity and favorable dose-dependent effects, reinforcing the drug's safety profile [6] Presentation and Recognition - The first poster on PALI-2108 was recognized as a Poster of Distinction at Digestive Disease Week 2025, showcasing its significance in the field of gastrointestinal disorders [2][5] Ongoing Clinical Studies - The company is conducting a Phase 1a/b single-center, double-blind, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers [7]